For many years, chronic obstructive pulmonary disease (COPD) was considered a disease
of fixed airflow obstruction for which there was no good treatment. Out of desperation and …

Highlights•Several phenotypes characterize chronic obstructive pulmonary disease
(COPD).•Response to pharmacological treatment in COPD is highly variable.•Guidelines …

Blood eosinophils are a potentially useful biomarker for guiding inhaled corticosteroid (ICS)
treatment decisions in COPD. We investigated whether existing blood eosinophil counts …

Background: Blood eosinophils may predict response to inhaled corticosteroids (ICS) in
chronic obstructive pulmonary disease (COPD) where ICS is recommended in patients at …

Chronic obstructive pulmonary disease (COPD) is a chronic, inflammatory lung disease
characterized by airflow limitation that is not fully reversible. The pathological changes in …

Background Chronic obstructive pulmonary disease (COPD) is associated with significant
morbidity and mortality. To improve the health status and reduce symptom burden, it is …

There is an emerging role for blood eosinophil count (EOS) as a biomarker to guide inhaled
corticosteroid (ICS) therapy in COPD. Since ICS administration could influence EOS, we …

Background COPD is a highly heterogeneous disease. Potential biomarkers to identify
patients with COPD who will derive the greatest benefit from inhaled corticosteroid (ICS) …

Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …

A number of recent post hoc analyses of clinical trials have demonstrated that higher blood
eosinophil counts predict greater inhaled corticosteroid (ICS) effects on exacerbation …